Article,DOI,Name,Origin sequence,Sequence,"Stability t1/2, h",Environment,"Concentration of envi, %","Temperature, oC",Type,"Melting temperature, oC",Modified,Comments
Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity,https://doi.org/10.1021/jacs.9b10460,GLB-A04,aUgAUCAAUcGCCUCAaUUCGACA8GAGGCuCaC,1tAFU1tGAFUFCAAFU1tFCGFCFCFUFCA1tAFUFUFCGAFCA2tGGAGGFC1tFUFC1tAFC,72,frozen human serum,95,37,DNA,,1,
Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity,https://doi.org/10.1021/jacs.9b10460,GLB-G25,aUg6UCAAUcGCCUCAaUUCGACAgGAGGCuCaC,1tAFU1tG2tAFUFCAAFU1tFCGFCFCFUFCA1tAFUFUFCGAFCA1tGGAGGFC1tFUFC1tAFC,72,frozen human serum,95,37,DNA,,1,
Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity,https://doi.org/10.1021/jacs.9b10460,GLB-A04,aUgAUCAAUcGCCUCAaUUCGACA8GAGGCuCaC,1tAFU1tGAFUFCAAFU1tFCGFCFCFUFCA1tAFUFUFCGAFCA2tGGAGGFC1tFUFC1tAFC,1.89,rat blood,100,38.8,DNA,,1,
Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity,https://doi.org/10.1021/jacs.9b10460,GLB-A04 PEG,peg-aUgAUCAAUcGCCUCAaUUCGACA8GAGGCuCaC,peg1tAFU1tGAFUFCAAFU1tFCGFCFCFUFCA1tAFUFUFCGAFCA2tGGAGGFC1tFUFC1tAFC,5.09,rat blood,100,38.8,DNA,,1,
Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity,https://doi.org/10.1021/jacs.9b10460,GLB-G25 PEG,peg-aUg6UCAAUcGCCUCAaUUCGACAgGAGGCuCaC,peg1tAFU1tG2tAFUFCAAFU1tFCGFCFCFUFCA1tAFUFUFCGAFCA1tGGAGGFC1tFUFC1tAFC,4.23,rat blood,100,38.8,DNA,,1,
Targeting Axl With an High-affinity Inhibitory Aptamer,https://doi.org/10.1038/mt.2012.163,GL21.T,AUGAUCAAUCGCCUCAAUUCGACAGGAGGCUCAC,AUGAUCAAUCGCCUCAAUUCGACAGGAGGCUCAC,6,fetal bovine serum,10,37,RNA,,0,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG1,d(GGTTGGTGTGGTTGG),GGTTGGTGTGGTTGG,0.5,fetal bovine serum,10,37,DNA,46.4,0,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG2,d(GGTTGGTGTGGTTGG),anaGanaGanaTanaTanaGanaGanaTanaGanaTanaGanaGanaTanaTanaGanaG,24,fetal bovine serum,10,37,DNA,47.4,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG3,d(GGTTGGTGTGGTTGG),GanaGTTGanaGTGTGanaGTTGanaG,4.8,fetal bovine serum,10,37,DNA,54.1,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG4,d(GGTTGGTGTGGTTGG),GanaGanaTanaTGanaGanaTanaGanaTGGTTGanaG,9.4,fetal bovine serum,10,37,DNA,53.3,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG5,d(GGTTGGTGTGGTTGG),anaGGTTanaGGTGTGGTTanaGG,0.8,fetal bovine serum,10,37,DNA,61.6,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG6,d(GGTTGGTGTGGTTGG),anaGGanaTanaTanaGGanaTanaGanaTanaGGanaTanaTanaGG,0.6,fetal bovine serum,10,37,DNA,45.4,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG7,d(GGTTGGTGTGGTTGG),anaGanaGTTanaGanaGTGTanaGanaGTTanaGanaG,4.0,fetal bovine serum,10,37,DNA,48.5,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG8,d(GGTTGGTGTGGTTGG),GGanaTanaTGGanaTanaGanaTGGanaTanaTGG,5.9,fetal bovine serum,10,37,DNA,50.2,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG9,d(GGTTGGTGTGGTTGG),GGanaTanaTGGanaTGanaTGGanaTanaTGG,2.8,fetal bovine serum,10,37,DNA,56.3,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG10,d(GGTTGGTGTGGTTGG),GGTanaTGGanaTGanaTGGTTGG,2.7,fetal bovine serum,10,37,DNA,57.1,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG11,d(GGTTGGTGTGGTTGG),GGanaTanaTGGanaTGanaTGGanaTTGG,5.1,fetal bovine serum,10,37,DNA,51.2,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG12,d(GGTTGGTGTGGTTGG),GGanaTanaTGGTGTGGanaTanaTGG,3.5,fetal bovine serum,10,37,DNA,56.6,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG13,d(GGTTGGTGTGGTTGG),GGTTGGanaTGanaTGGanaTanaTGG,3.4,fetal bovine serum,10,37,DNA,59.1,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,PG14,d(GGTTGGTGTGGTTGG),GGanaTanaTGGanaTGanaTGGTTGG,2.0,fetal bovine serum,10,37,DNA,51.0,1,
G-quadruplex induced stabilization by 2′-deoxy-2′-fluoro-d-arabinonucleic acids (2′F-ANA),https://doi.org/10.1093/nar/gkm520,P8,d(GTCTCTTGTGTGACTCTGGTAAC),GTCTCTTGTGTGACTCTGGTAAC,0.5,fetal bovine serum,10,37,DNA,50.6,0,
Anticoagulant effects of thioanalogs of thrombin-binding DNA-aptamer and their stability in the plasma,https://doi.org/10.1007/s10517-010-1099-5,TBA,GGTTGGTGTGGTTGG,,Mass-spec,citrate-stabilized plasma,100,37,DNA,52,0,
,,P4,gGTTgGTGTgGTTgG*,,,citrate-stabilized plasma,100,37,DNA,40,1,
,,SATR,ggttggtgtggttgG,,,citrate-stabilized plasma,100,37,DNA,45,1,
,,P511,GGTTgGTGTgGTTGG,,,citrate-stabilized plasma,100,37,DNA,46,1,
,,P111,gGTTGGTGTgGTTGG,,,citrate-stabilized plasma,100,37,DNA,47,1,
,,P1011,GGTTGGTGTgGTTGG,,,citrate-stabilized plasma,100,37,DNA,49,1,
,,L3,GGttGTGTGGTTGG,,,citrate-stabilized plasma,100,37,DNA,52,1,
,,LL11,GgttGGTGTGgttGG,,Mass-spec,citrate-stabilized plasma,100,37,DNA,54,1,
,,L1,GGTTGGTGTGGtTGG,,,citrate-stabilized plasma,100,37,DNA,55,1,
,,L11,GGtTGGTGTGGtTGG,,,citrate-stabilized plasma,100,37,DNA,55,1,
,,LL,GgttGgtgtGgttGG,,,citrate-stabilized plasma,100,37,DNA,55,1,
,,L121,GGtTGGtgTGGtTGG,,,citrate-stabilized plasma,100,37,DNA,56,1,
Conformation and thermostability of oligonucleotide d(GGTTGGTGTGGTTGG) containing thiophosphoryl internucleotide bonds at different positions,https://doi.org/10.1016/j.bpc.2009.09.011,TBA,GGTTGGTGTGGTTGG,,Mass-spec,citrate-stabilized plasma,100,37,DNA,52,0,Уточнить расположение модификаций: до или после нуклеотида (должно быть до)
,,P1011,d(GGTTGGTGTGsGTTGG),,,citrate-stabilized plasma,100,37,DNA,49,1,
,,P4,d(GsGTTGsGTGTGsGTTGsG),,,citrate-stabilized plasma,100,37,DNA,40,1,
,,P1415,d(GGTTGGTGTGGTTGsG),,,citrate-stabilized plasma,100,37,DNA,50,1,
,,P111,d(GsGTTGGTGTGsGTTGsG),,,citrate-stabilized plasma,100,37,DNA,47,1,
,,P511,d(GGTTGsGTGTGsGTTGsG),,,citrate-stabilized plasma,100,37,DNA,46,1,
,,L1,d(GGTTGGTGTGGTsTGG),,,citrate-stabilized plasma,100,37,DNA,55,1,
,,L11,d(GGTsTGGTGTGGTsTGG),,,citrate-stabilized plasma,100,37,DNA,55,1,
,,L121,d(GGTsTGGTsGsTGGTsTGG),,,citrate-stabilized plasma,100,37,DNA,56,1,
,,LL11,d(GGsTsTsGGTGTGGsTsTsGG),,Mass-spec,citrate-stabilized plasma,100,37,DNA,54,1,
,,LL ,d(GGsTsTsGGsTsGsTsGGsTsTsGG),,,citrate-stabilized plasma,100,37,DNA,55,1,
,,L343,d(GGTsTsGsGTsGsTsGsGsTsTsGsG),,,citrate-stabilized plasma,100,37,DNA,46,1,
,,L3 ,d(GGTsTsGsGTGTGGTTGG),,,citrate-stabilized plasma,100,37,DNA,52,1,
,,SATR,d(GsGsTsTsGsGsTsGsTsGsGsTsTsGsG),,,citrate-stabilized plasma,100,37,DNA,45,1,
In Vivo Anticoagulant Properties of a Novel Nucleotide-Based Thrombin Inhibitor and Demonstration of Regional Anticoagulation in Extracorporeal Circuits,https://doi.org/10.1182/blood.V81.12.3271.3271,TBA,GGTTGGTGTGGTTGG,GGTTGGTGTGGTTGG,0.03,macaca fascicularis blood,100,38.25,DNA,,0,
Synthesis of triazole-linked oligonucleotides with high affinity to DNA complements and an analysis of their compatibility with biosystems,https://doi.org/10.1021/jo400651k,,TtrTAACTTCTtrTCACATtrTC,TtrTAACTTCTtrTCACATtrTC,0.5,Buffer + DNase I,,,DNA,,1,
Pharmacokinetics of a Cholesterol-conjugated Aptamer Against the Hepatitis C Virus (HCV) NS5B Protein,https://doi.org/10.1038/mtna.2015.30,aptamer against HCV NS5B,cholUUGAACGAUUGGUAGUAGAAUAUCGUCAGidt,cholfUfUGAAfCGAfUfUGGfUAGfUAGAAfUAfUfCGfUfCAGidt,11,rat blood,100,38.8,RNA,,1,
Pharmacokinetics of a Cholesterol-conjugated Aptamer Against the Hepatitis C Virus (HCV) NS5B Protein,https://doi.org/10.1038/mtna.2015.30,aptamer against HCV NS5B,UUGAACGAUUGGUAGUAGAAUAUCGUCAG,fUfUGAAfCGAfUfUGGfUAGfUAGAAfUAfUfCGfUfCAG,5.8,rat blood,100,38.8,RNA,,1,
Inhibition of Hepatitis C Virus (HCV) Replication by Specific RNA Aptamers against HCV NS5B RNA Replicase,https://doi.org/10.1128/JVI.00405-13,chol–R-F t2,UUGAACGAUUGGUAGUAGAAUAUCGUCAG,cholfUfUGAAfCGAfUfUGGfUAGfUAGAAfUAfUfCGfUfCAGidt,11.03,rat liver,100,38.8,RNA,,1,
Inhibition of Hepatitis C Virus (HCV) Replication by Specific RNA Aptamers against HCV NS5B RNA Replicase,https://doi.org/10.1128/JVI.00405-13,Gal-PEG–R-F t2,galpegUUGAACGAUUGGUAGUAGAAUAUCGUCAG,gpegfUfUGAAfCGAfUfUGGfUAGfUAGAAfUAfUfCGfUfCAG,3.79,rat liver,100,38.8,RNA,,1,
"5′-,3′-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine",https://doi.org/10.1074/jbc.M112100200,"5′-,3′-inverted T AS",TAGGGCGAGAAGGAAGAAGT,idtAGGGCGAGAAGGAAGAAGidt,30,fetal bovine serum,5,37,DNA,,1,
"5′-,3′-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine",https://doi.org/10.1074/jbc.M112100200,3′-inverted T AS,AGGGCGAGAAGGAAGAAGT,AGGGCGAGAAGGAAGAAGidt,110,fetal bovine serum,5,37,DNA,,1,
"5′-,3′-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine",https://doi.org/10.1074/jbc.M112100200,PS AS,agggcgagaaggaagaag,tpAtpGtpGtpGtpCtpGtpAtpGtpAtpAtpGtpGtpAtpAtpGtpAtpAtpG,10,fetal bovine serum,5,37,DNA,,1,
"5′-,3′-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine",https://doi.org/10.1074/jbc.M112100200,"5′-,3′-non-inverted T AS",TAGGGCGAGAAGGAAGAAGT,TAGGGCGAGAAGGAAGAAGT,5,fetal bovine serum,5,37,DNA,,0,
Pharmacokinetics of antisense oligonucleotides,https://doi.org/10.2165/00003088-199528010-00002,25-mer P,CTCTCGCACCCATCTCTCTCCTTCT,CTCTCGCACCCATCTCTCTCCTTCT,0.08,rhesus monkey blood,100,38.25,DNA,,0,
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate,https://pubmed.ncbi.nlm.nih.gov/8190109/,20-mer P,ACACCCAATTCTGAAAATGG,ACACCCAATTCTGAAAATGG,0.08,rat blood,100,38.8,DNA,,0,Указано в сноске в https://doi.org/10.2165/00003088-199528010-00002
Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single i.v. injection in mice,https://pubmed.ncbi.nlm.nih.gov/1981742/,12-mer M,TTCCTCCTGCGG,mpTmpTmpCmpCmpTmpCmpCmpTmpGmpCmpGmpG,0.1,rat blood,100,38.8,DNA,,1,Указано в сноске в https://doi.org/10.2165/00003088-199528010-00002
Pharmacokinetics of antisense oligonucleotides,https://doi.org/10.2165/00003088-199528010-00002,20-mer S,ACACCCAATTCTGAAAATGG,tpAtpCtpAtpCtpCtpCtpAtpAtpTtpTtpCtpTtpGtpAtpAtpAtpAtpTtpGtpG,0.53,rat blood,100,38.8,DNA,,1,
Pharmacokinetics of antisense oligonucleotides,https://doi.org/10.2165/00003088-199528010-00002,GEM91,CTCTCGCACCCATCTCTCTCCTTCT,tpCtpTtpCtpTtpCtpGtpCtpAtpCtpCtpCtpAtpTtpCtpTtpCtpTtpCtpTtpCtpCtpTtpTtpCtpT,0.97,rat blood,100,38.8,DNA,,1,
Pharmacokinetics of antisense oligonucleotides,https://doi.org/10.2165/00003088-199528010-00002,GEM91,CTCTCGCACCCATCTCTCTCCTTCT,tpCtpTtpCtpTtpCtpGtpCtpAtpCtpCtpCtpAtpTtpCtpTtpCtpTtpCtpTtpCtpCtpTtpTtpCtpT,0.8,rhesus monkey blood,100,38.25,DNA,,1,
Pharmacokinetics of antisense oligonucleotides,https://doi.org/10.2165/00003088-199528010-00002,GEM91,CTCTCGCACCCATCTCTCTCCTTCT,tpCtpTtpCtpTtpCtpGtpCtpAtpCtpCtpCtpAtpTtpCtpTtpCtpTtpCtpTtpCtpCtpTtpTtpCtpT,0.18,human blood,100,36.6,DNA,,1,
Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor,https://doi.org/10.1074/jbc.M113.532580,SL1023,GGCAGGbnUbnUbnUGGbnUAbnUbnUAACACGbnUbnUAAGbnUCGbnUGGidt,GGCAGGbnUbnUbnUGGbnUAbnUbnUAACACGbnUbnUAAGbnUCGbnUGGidt,50,frozen human serum,90,37,SOMAmer,,1,
Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor,https://doi.org/10.1074/jbc.M113.532580,SL1023dT,GGCAGGTTTGGTATTAACACGTTAAGTCGTGGidt,GGCAGGTTTGGTATTAACACGTTAAGTCGTGGidt,5.5,frozen human serum,90,37,SOMAmer,,1,
Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor,https://doi.org/10.1074/jbc.M113.532580,SL1025,GGomeCAGomeGbnUbnUpeUGGnapUAbnUbnUomeAAComeAomeCGbnUbnUAAGbnUomeCGbnUGGidt,GGomeCAGomeGbnUbnUpeUGGnapUAbnUbnUomeAAComeAomeCGbnUbnUAAGbnUomeCGbnUGGidt,Не указано. По графику?,frozen human serum,90,37,SOMAmer,,1,
Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor,https://doi.org/10.1074/jbc.M113.532580,SL1031,GGGGnapUnapUAnapUGnapUAGCGAGnapUGCGnapUAAGGCGGnapUGidt,GGGGnapUnapUAnapUGnapUAGCGAGnapUGCGnapUAAGGCGGnapUGidt,77,frozen human serum,90,37,SOMAmer,,1,
Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor,https://doi.org/10.1074/jbc.M113.532580,SL1031dT,GGGGTTATGTAGCGAGTGCGTAAGGCGGTGidt,GGGGTTATGTAGCGAGTGCGTAAGGCGGTGidt,8.5,frozen human serum,90,37,SOMAmer,,1,
Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor,https://doi.org/10.1074/jbc.M113.532580,SL1032,LGGGnapUnapUAnapUGnapAGCLLGnapUGCGnapUAAGGCGGnapUGidt,LGGGnapUnapUAnapUGnapAGCLLGnapUGCGnapUAAGGCGGnapUGidt,Не указано. По графику?,frozen human serum,90,37,SOMAmer,,1,
Nuclease resistant ribozymes with high catalytic activity,https://doi.org/10.1002/j.1460-2075.1992.tb05244.x,hammerhead ribozyme against the EDB exon 426,alUalGalUalGalUalCAalAalAGalCalAalGalGalAalGalUalGalCalCalUalGalAGalUAGUalCalUalGalUalCalCalCalG,alUalGalUalGalUalCAalAalAGalCalAalGalGalAalGalUalGalCalCalUalGalAGalUAGUalCalUalGalUalCalCalCalG,0.74,bovine serum,100,37,ribozyme,,1,
Nuclease resistant ribozymes with high catalytic activity,https://doi.org/10.1002/j.1460-2075.1992.tb05244.x,hammerhead ribozyme against the EDB exon 474,UGUGUCAAAGCAGGAGUGCCUGAGUAGUCUGUCCCG,UGUGUCAAAGCAGGAGUGCCUGAGUAGUCUGUCCCG,0.016,bovine serum,100,37,ribozyme,,0,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,R32,CGGCAAAGCCGGAAAGCCGGAGUAGUCGGGGC,CGGCAAAGCCGGAAAGCCGGAGUAGUCGGGGC,0.08,fetal bovine serum,0.1,37,ribozyme,,0,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,DRD32,dCdGdGCAAAGCCGGAAAGCCGGAGUAGUCdGdGdGdGdC,dCdGdGCAAAGCCGGAAAGCCGGAGUAGUCdGdGdGdGdC,0.08,fetal bovine serum,0.1,37,ribozyme,,1,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,DRDRD32,dCdGdGCAAAGdCdCdGdGdAdAdAdGdCdCdGdGAGUAGUCdGdGdGdGdC,dCdGdGCAAAGdCdCdGdGdAdAdAdGdCdCdGdGAGUAGUCdGdGdGdGdC,0.08,fetal bovine serum,0.1,37,ribozyme,,1,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,thio-DRDRD32,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAGUAGUtpCdtpGdtpGdtpGdtpGdtpC,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAGUAGUtpCdtpGdtpGdtpGdtpGdtpC,0.08,fetal bovine serum,0.1,37,ribozyme,,1,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,thio-DRDRD32-3S,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAtpGUAtpGtpUtpCdtpGdtpGdtpGdtpGdtpC,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAtpGUAtpGtpUtpCdtpGdtpGdtpGdtpGdtpC,15.73,fetal bovine serum,0.1,37,ribozyme,,1,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,thio-DRDRD32-2SA,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAGAAtpGtpUtpCdtpGdtpGdtpGdtpGdtpC,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAGAAtpGtpUtpCdtpGdtpGdtpGdtpGdtpC,Не указано. По графику?,fetal bovine serum,0.1,37,ribozyme,,1,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,thio-DRDRD32-2SG,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAGGAtpGtpUtpCdtpGdtpGdtpGdtpGdtpC,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAGGAtpGtpUtpCdtpGdtpGdtpGdtpGdtpC,Не указано. По графику?,fetal bovine serum,0.1,37,ribozyme,,1,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,R32,CGGCAAAGCCGGAAAGCCGGAGUAGUCGGGGC,CGGCAAAGCCGGAAAGCCGGAGUAGUCGGGGC,0.042,frozen human serum,20,37,ribozyme,,1,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,DRDRD32,dCdGdGCAAAGdCdCdGdGdAdAdAdGdCdCdGdGAGUAGUCdGdGdGdGdC,dCdGdGCAAAGdCdCdGdGdAdAdAdGdCdCdGdGAGUAGUCdGdGdGdGdC,0.67,frozen human serum,20,37,ribozyme,,1,
Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages,https://pmc.ncbi.nlm.nih.gov/articles/PMC309588/,thio-DRDRD32-2SA,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAGAAtpGtpUtpCdtpGdtpGdtpGdtpGdtpC,dtpCdtpGdtpGCAAAtpGdtpCdtpCdtpGdtpGdtpAdtpAdtpAdtpGdtpCdtpCdtpGdtpGAGAAtpGtpUtpCdtpGdtpGdtpGdtpGdtpC,2.8,frozen human serum,20,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 1,UCUCCAUCUGAUGAGGCCGAAAGGCCGAAAAUCCCU,UCUCCAUCUGAUGAGGCCGAAAGGCCGAAAAUCCCU,0.002,human serum,100,37,ribozyme,,0,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 2,ucuccAUCUGAUGAGGCCGAAAGGCCGAAAAucccU,omeUomeComeUomeComeCAUCUGAUGAGGCCGAAAGGCCGAAAAomeUomeComeComeCU,0.002,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 3,ucuccaUCUGAUGAGGCCGAAAGGCCGAAAaucccu,tpUtpCtpUtpCtpCAUCUGAUGAGGCCGAAAGGCCGAAAAtpUtpCtpCtpCtpU,0.002,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 4,ucuccAucuGAuGAGGCCGAAAGGCCGAAAAuccct,alUalCalUalCalCAalUalCalUGAalUGAGGCCGAAAGGCCGAAAAalUalCalCalCT,2,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 5,ucuccAucuGAuGAGGccGAAAGGccGAAAAuccct,fUfCfUfCfCAfUfCfUGAfUGAGGfCfCGAAAGGfCfCGAAAAfUfCfCfCT,0.25,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 6,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCUGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,0.002,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 7,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeComeUGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,4.33,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 8,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCch2UGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,4.17,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 9,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeComeUGAch2UGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,5.33,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 10,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCch2UGAch2UGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,4.17,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 11,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeC2fcUGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,6.67,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 12,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeComeUGA2fcUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,4.17,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 13,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeC2fcUGA2fcUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,6.33,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 14,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCfUGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,5,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 15,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeComeUGAfUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,5,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 16,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCfUGAfUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,5,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 17,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCdUGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,4.17,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 18,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeComeUGAdUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,4.17,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 19,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCdUGAdUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,4.67,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 20,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCanaUGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,8.33,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 21,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeComeUGAanaUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,5.83,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 22,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCanaUGAanaUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,8.33,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 23,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCamUGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,8.33,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 24,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeComeUGAamUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,8.33,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 25,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCamUGAamUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,5,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 26,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCalUGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,8.33,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 27,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeComeUGAalUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,5,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 28,ucuccaucuGAuGaggccgaaaggccGaaAaucccu,omeUomeComeUomeComeComeAomeUomeCalUGAalUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeU,5,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 29,ucuccaucuGAuGaggccgaaaggccGaaAaucccuX,omeUomeComeUomeComeComeAomeUomeCalUGAomeUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeUidt,266.67,human serum,100,37,ribozyme,,1,
Chemical Modification of Hammerhead Ribozymes CATALYTIC ACTIVITY AND NUCLEASE RESISTANCE,https://doi.org/10.1074/jbc.270.43.25702,Rz 30,ucuccaucuGAuGaggccgaaaggccGaaAaucccuX,omeUomeComeUomeComeComeAomeUomeCamUGAamUGomeAomeGomeGomeComeComeGomeAomeAomeAomeGomeGomeComeCGomeAomeAAomeAomeUomeComeComeComeUidt,266.67,human serum,100,37,ribozyme,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LF1807 dC,ggAGUCUUAGGCAGCGCGUUUUCGAGCUACUCCA,dsaGGAGfUfCfUfUAGGfCAGfCGfCGfUfUfUfUfCGAGfCfUAfCfUfCfCAidt,0.165,rat blood,100,38.8,RNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LF1807 bD,ggAGUCUUAGGCAGCGCGUUUUCGAGCUACUCCA,dspeamdTGGAGfUfCfUfUAGGfCAGfCGfCGfUfUfUfUfCGAGfCfUAfCfUfCfCAidtdT,0.178,rat blood,100,38.8,RNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LF1807 d20,ggAGUCUUAGGCAGCGCGUUUUCGAGCUACUCCA,papeg20GGAGfUfCfUfUAGGfCAGfCGfCGfUfUfUfUfCGAGfCfUAfCfUfCfCAidt,0.86,rat blood,100,38.8,RNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LF1807 b20,ggAGUCUUAGGCAGCGCGUUUUCGAGCUACUCCA,peg20amdTGGAGfUfCfUfUAGGfCAGfCGfCGfUfUfUfUfCGAGfCfUAfCfUfCfCAidtdT,1.17,rat blood,100,38.8,RNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LF1807 d40,ggAGUCUUAGGCAGCGCGUUUUCGAGCUACUCCA,papeg40GGAGfUfCfUfUAGGfCAGfCGfCGfUfUfUfUfCGAGfCfUAfCfUfCfCAidt,3.8,rat blood,100,38.8,RNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LD201 b,CCAGTACAAGGTGCTAAACGTAATGG,amTfCfCAGfTAfCAAGGfTGfCfTAAAfCGfTAAfTGGidtT,0.05,rat blood,100,38.8,DNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LD201 bD,CCAGTACAAGGTGCTAAACGTAATGG,dspeamTfCfCAGfTAfCAAGGfTGfCfTAAAfCGfTAAfTGGidtT,0.285,rat blood,100,38.8,DNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LD201 a,tagccaAGGTAACCAGTACAAGGTGCTAAACGTAATGGCTTCggcttac,fTAGfCfCAAGGfTAAfCfCAGfTAfCAAGGfTGfCfTAAAfCGfTAAfTGGfCfTfTfCGGfCfTfTAfC,0.12,rat blood,100,38.8,DNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LD201 b20,CCAGTACAAGGTGCTAAACGTAATGG,peg20amTfCfCAGfTAfCAAGGfTGfCfTAAAfCGfTAAfTGGidtT,0.375,rat blood,100,38.8,DNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LD201 d20,tagccaAGGTAACCAGTACAAGGTGCTAAACGTAATGGCTTCggcttac,papeg20fTAGfCfCAAGGfTAAfCfCAGfTAfCAAGGfTGfCfTAAAfCGfTAAfTGGfCfTfTfCGGfCfTfTAfCidtT,0.2,rat blood,100,38.8,DNA,,1,
"Anti-L-selectin aptamers binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo",https://doi.org/10.1089/oli.1.2000.10.63,LD174 b40,tagccaTTCACCATGGCCCCTTCCTACGTATGTTCTGCGGGTggctta,peg40amTfTAGfCfCAfTfTfCAfCfCAfTGGfCfCfCfCfTfTfCfCfTAfCGfTAfTGfTfTfCfTGfCGGGfTGGfCfTfTAidtT,0.253,rat blood,100,38.8,DNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,DNA T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGCGTAGTGATTATGAATCGTGTGCTAATACACGCCidt,8.2,human serum,100,37,DNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,DNA C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGCGTAGTGATTATGAATCGTGTGCTAATACACGCC,4.9,human serum,100,37,DNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fYrR T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGfCGfUAGfUGAfUfUAfUGAAfUfCGfUGfUGfCfUAAfUAfCAfCGfCfCidt,12,human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fYrR C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGfCGfUAGfUGAfUfUAfUGAAfUfCGfUGfUGfCfUAAfUAfCAfCGfCfC,10,human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fGmH T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolfGfGomeCfGomeUomeAfGomeUfGomeAomeUomeUomeAomeUfGomeAomeAomeUomeCfGomeUfGomeUfGomeComeUomeAomeAomeUomeAomeComeAomeCfGomeComeCidt,240,human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fGmH C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolfGfGomeCfGomeUomeAfGomeUfGomeAomeUomeUomeAomeUfGomeAomeAomeUomeCfGomeUfGomeUfGomeComeUomeAomeAomeUomeAomeComeAomeCfGomeComeC,240,human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,OMe T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolomeGomeGomeComeGomeUomeAomeGomeUomeGomeAomeUomeUomeAomeUomeGomeAomeAomeUomeComeGomeUomeGomeUomeGomeComeUomeAomeAomeUomeAomeComeAomeComeGomeComeCidt,240,human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,OMe C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolomeGomeGomeComeGomeUomeAomeGomeUomeGomeAomeUomeUomeAomeUomeGomeAomeAomeUomeComeGomeUomeGomeUomeGomeComeUomeAomeAomeUomeAomeComeAomeComeGomeComeC,240,human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,A9.min,5S GGGACCGAAAAAGACCUGACUUCUAUACUAAGUCUACGUUCCC(t),thiolGGGAfCfCGAAAAAGAfCfCfUGAfCfUfUfCfUAfUAfCfUAAGfUfCfUAfCGfUfUfCfCfCidt,3.8,human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,DNA T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGCGTAGTGATTATGAATCGTGTGCTAATACACGCCidt,16,frozen human serum,100,37,DNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,DNA C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGCGTAGTGATTATGAATCGTGTGCTAATACACGCC,6,frozen human serum,100,37,DNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fYrR T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGfCGfUAGfUGAfUfUAfUGAAfUfCGfUGfUGfCfUAAfUAfCAfCGfCfCidt,9.9,frozen human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fYrR C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGfCGfUAGfUGAfUfUAfUGAAfUfCGfUGfUGfCfUAAfUAfCAfCGfCfC,11,frozen human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fGmH T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolfGfGomeCfGomeUomeAfGomeUfGomeAomeUomeUomeAomeUfGomeAomeAomeUomeCfGomeUfGomeUfGomeComeUomeAomeAomeUomeAomeComeAomeCfGomeComeCidt,240,frozen human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fGmH C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolfGfGomeCfGomeUomeAfGomeUfGomeAomeUomeUomeAomeUfGomeAomeAomeUomeCfGomeUfGomeUfGomeComeUomeAomeAomeUomeAomeComeAomeCfGomeComeC,240,frozen human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,OMe T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolomeGomeGomeComeGomeUomeAomeGomeUomeGomeAomeUomeUomeAomeUomeGomeAomeAomeUomeComeGomeUomeGomeUomeGomeComeUomeAomeAomeUomeAomeComeAomeComeGomeComeCidt,240,frozen human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,OMe C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolomeGomeGomeComeGomeUomeAomeGomeUomeGomeAomeUomeUomeAomeUomeGomeAomeAomeUomeComeGomeUomeGomeUomeGomeComeUomeAomeAomeUomeAomeComeAomeComeGomeComeC,240,frozen human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,A9.min,5S GGGACCGAAAAAGACCUGACUUCUAUACUAAGUCUACGUUCCC(t),thiolGGGAfCfCGAAAAAGAfCfCfUGAfCfUfUfCfUAfUAfCfUAAGfUfCfUAfCGfUfUfCfCfCidt,8.0,frozen human serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,DNA T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGCGTAGTGATTATGAATCGTGTGCTAATACACGCCidt,1.8,mouse serum,100,37,DNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,DNA C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGCGTAGTGATTATGAATCGTGTGCTAATACACGCC,1.6,mouse serum,100,37,DNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fYrR T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGfCGfUAGfUGAfUfUAfUGAAfUfCGfUGfUGfCfUAAfUAfCAfCGfCfCidt,2.5,mouse serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fYrR C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolGGfCGfUAGfUGAfUfUAfUGAAfUfCGfUGfUGfCfUAAfUAfCAfCGfCfC,2.2,mouse serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fGmH T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolfGfGomeCfGomeUomeAfGomeUfGomeAomeUomeUomeAomeUfGomeAomeAomeUomeCfGomeUfGomeUfGomeComeUomeAomeAomeUomeAomeComeAomeCfGomeComeCidt,180,mouse serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,fGmH C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolfGfGomeCfGomeUomeAfGomeUfGomeAomeUomeUomeAomeUfGomeAomeAomeUomeCfGomeUfGomeUfGomeComeUomeAomeAomeUomeAomeComeAomeCfGomeComeC,110,mouse serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,OMe T,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolomeGomeGomeComeGomeUomeAomeGomeUomeGomeAomeUomeUomeAomeUomeGomeAomeAomeUomeComeGomeUomeGomeUomeGomeComeUomeAomeAomeUomeAomeComeAomeComeGomeComeCidt,230,mouse serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,OMe C,5S GGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCC(t),thiolomeGomeGomeComeGomeUomeAomeGomeUomeGomeAomeUomeUomeAomeUomeGomeAomeAomeUomeComeGomeUomeGomeUomeGomeComeUomeAomeAomeUomeAomeComeAomeComeGomeComeC,75,mouse serum,100,37,RNA,,1,
Effect of Chemical Modifications on Aptamer Stability in Serum,https://doi.org/10.1089/nat.2017.0680,A9.min,5S GGGACCGAAAAAGACCUGACUUCUAUACUAAGUCUACGUUCCC(t),thiolGGGAfCfCGAAAAAGAfCfCfUGAfCfUfUfCfUAfUAfCfUAAGfUfCfUAfCGfUfUfCfCfCidt,2.5,mouse serum,100,37,RNA,,1,
Novel Approach to Specific Growth Factor Inhibition in Vivo,https://doi.org/10.1016/S0002-9440(10)65263-7,PDGF aptamer,CAGGCTACGGCACGTAGAGCATCACCATGATCCTTG[3T],CAGGCTACGGCACGTAGAGCATCACCATGATCCTGidt,0.6,rat serum,85,37,DNA,,0,
Novel Approach to Specific Growth Factor Inhibition in Vivo,https://doi.org/10.1016/S0002-9440(10)65263-7,PDGF aptamer modified,CAGGCTACGGCACGTAGAGCATCACCATGATCCTTG[3T],peg40CAGGCfrUAfComeGheglCGTAomeGAomeGCAfrUfCAheglTGATfCfCfrUomeGidt,8,rat serum,85,37,DNA,,1,
Novel Approach to Specific Growth Factor Inhibition in Vivo,https://doi.org/10.1016/S0002-9440(10)65263-7,PDGF aptamer modified,CAGGCTACGGCACGTAGAGCATCACCATGATCCTTG[3T],peg40CAGGCfrUAfComeGheglCGTAomeGAomeGCAfrUfCAheglTGATfCfCfrUomeGidt,0.54,rat blood,100,37,DNA,,1,
Highly Stable Aptamers Selected from a 2′-Fully Modified fGmH RNA Library for Targeting Biomaterials,https://doi.org/10.1016/j.biomaterials.2014.08.046,WT A12,UGUAAUUCUGCCAUUCUUUUUGGGGCGGAAUACAGGAUGU,UGUAAUUCUGCCAUUCUUUUUGGGGCGGAAUACAGGAUGU,0.08,rat serum,10,37,RNA,,0,
Highly Stable Aptamers Selected from a 2′-Fully Modified fGmH RNA Library for Targeting Biomaterials,https://doi.org/10.1016/j.biomaterials.2014.08.046,bmA12,UGUAAUUCUGCCAUUCUUUUUGGGGCGGAAUACAGGAUGU,fUGfUAAfUfUfCfUGfCfCAfUfUfCfUfUfUfUfUGGGGfCGGAAfUAfCAGGAfUGfU,15,rat serum,10,37,RNA,,1,
Highly Stable Aptamers Selected from a 2′-Fully Modified fGmH RNA Library for Targeting Biomaterials,https://doi.org/10.1016/j.biomaterials.2014.08.046,tmA12,UGUAAUUCUGCCAUUCUUUUUGGGGCGGAAUACAGGAUGU,omeUGomeUomeAomeAomeUomeUomeComeUGomeComeComeAomeUomeUomeComeUomeUomeUomeUomeUGGGGomeCGGomeAomeAomeUomeAomeComeAGGomeAomeUGomeU,"29,5",rat serum,10,37,RNA,,1,
Highly Stable Aptamers Selected from a 2′-Fully Modified fGmH RNA Library for Targeting Biomaterials,https://doi.org/10.1016/j.biomaterials.2014.08.046,fmA12,UGUAAUUCUGCCAUUCUUUUUGGGGCGGAAUACAGGAUGU,omeUfGomeUomeAomeAomeUomeUomeComeUfGomeComeComeAomeUomeUomeComeUomeUomeUomeUomeUfGfGfGfGomeCfGfGomeAomeAomeUomeAomeComeAfGfGomeAomeUfGomeU,52,rat serum,10,37,RNA,,1,
"A High Affinity, Antidote-Controllable Prothrombin and Thrombin-Binding RNA Aptamer Inhibits Thrombin Generation and Thrombin Activity",https://doi.org/10.1111/j.1538-7836.2012.04679.x,RNAR9D-14T,GG(2'F-C)GG(2'F-U)(2'F-C)GA(2'F-U)(2'F-C)A(2'F-C)A(2'F-C)AG(2'F-U)(2'F-U)(2'F-C)AAA(2'F-C)G(2'F-U)AA(2'F-U)AAG(2'F-C)(2'F-C)AA(2'F-U)G(2'F-U)A(2'F-C)GAGG(2'F-C)AGA(2'F-C)GA(2'F-C)(2'F-U)(2'F-C)G(2'F-C)(2'F-C),GGfCGGfUfCGAfUfCAfCAfCAGfUfUfCAAAfCGfUAAfUAAGfCfCAAfUGfUAfCGAGGfCAGAfCGAfCfUfCGfCfC,6,frozen human serum,100,37,RNA,,1,
"A High Affinity, Antidote-Controllable Prothrombin and Thrombin-Binding RNA Aptamer Inhibits Thrombin Generation and Thrombin Activity",https://doi.org/10.1111/j.1538-7836.2012.04679.x,ARC-183,GGTTGGTGTGGTTGG,GGTTGGTGTGGTTGG,2,frozen human serum,100,37,DNA,,0,
Intramolecular G-quartet Motifs Confer Nuclease Resistance to a Potent Anti-HIV Oligonucleotide,https://doi.org/10.1074/jbc.271.10.5698,T30177,g*tg gtg ggt@ggg tgg g*t-OH,GtpTGGTGGGTGGGTGGGtpT,100,bovine serum,100,37,DNA,,1,
Intramolecular G-quartet Motifs Confer Nuclease Resistance to a Potent Anti-HIV Oligonucleotide,https://doi.org/10.1074/jbc.271.10.5698,T30175,gtg gtg g@gt ggg tgg gt-OH,GTGGTGGGTGGGTGGGT,5,bovine serum,100,37,DNA,,0,
Intramolecular G-quartet Motifs Confer Nuclease Resistance to a Potent Anti-HIV Oligonucleotide,https://doi.org/10.1074/jbc.271.10.5698,T30527,t*gt agc tgc@aat tca c*g-OH,TtpGTAGCTGCAATTCACtpG,0.12,bovine serum,100,37,DNA,,1,
Intramolecular G-quartet Motifs Confer Nuclease Resistance to a Potent Anti-HIV Oligonucleotide,https://doi.org/10.1074/jbc.271.10.5698,T30526,gtg Atg ggt@ggg tgg gt-OH,GTGATGGGTGGGTGGGT,0.05,bovine serum,100,37,DNA,,0,
Intramolecular G-quartet Motifs Confer Nuclease Resistance to a Potent Anti-HIV Oligonucleotide,https://doi.org/10.1074/jbc.271.10.5698,T30523,tgt agc tgc@aat tca cg-OH,TGTAGCTGCAATTCACG,0.05,bovine serum,100,37,DNA,,0,
"Cellular uptake, distribution, and stability of 10-23 deoxyribozymes",https://doi.org/10.1089/108729002761381276,RS5,TGAGGGGCAGGCTAGCTACAACGACGTCGTGAC,TGAGGGGCAGGCTAGCTACAACGACGTCGTGAC,75,frozen human serum,100,37,DNAzyme,,0,
"Cellular uptake, distribution, and stability of 10-23 deoxyribozymes",https://doi.org/10.1089/108729002761381276,RS6,TGAGGGGCAGGCTAGCTACAACGACGTCGTGAC,TGAGGGGCAGGCTAGCTACAACGACGTCGTGAiC,21,frozen human serum,100,37,DNAzyme,,1,
"Cellular uptake, distribution, and stability of 10-23 deoxyribozymes",https://doi.org/10.1089/108729002761381276,RS5,TGAGGGGCAGGCTAGCTACAACGACGTCGTGAC,TGAGGGGCAGGCTAGCTACAACGACGTCGTGAC,75,human plasma,100,37,DNAzyme,,0,
"Cellular uptake, distribution, and stability of 10-23 deoxyribozymes",https://doi.org/10.1089/108729002761381276,RS6,TGAGGGGCAGGCTAGCTACAACGACGTCGTGAC,TGAGGGGCAGGCTAGCTACAACGACGTCGTGAiC,21,human plasma,100,37,DNAzyme,,1,
Antisense Effect of Oligodeoxynucleotides with Inverted Terminal Internucleotidic Linkages A Minimal Modification Protecting against Nucleolytic Degradation,https://doi.org/10.1089/ard.1992.2.129,SV40TAS35,TCTCTGTTTAAAACTTTATCCATCTTTGCAAAGCT,TCTCTGTTTAAAACTTTATCCATCTTTGCAAAGCT,0.33,human serum,100,37,DNA,,0,
Antisense Effect of Oligodeoxynucleotides with Inverted Terminal Internucleotidic Linkages A Minimal Modification Protecting against Nucleolytic Degradation,https://doi.org/10.1089/ard.1992.2.129,SV40TAS35-INV,iTCTCTGTTTAAAACTTTATCCATCTTTGCAAAGCiT,iTCTCTGTTTAAAACTTTATCCATCTTTGCAAAGCiT,30,human serum,100,37,DNA,,1,
Design of antisense oligonucleotides stabilized by locked nucleic acids,https://doi.org/10.1093/nar/30.9.1911,DNA 1,CATGTCATGACGGTTAGG,CATGTCATGACGGTTAGG,1.5,frozen human serum,100,37,DNA,,0,
Design of antisense oligonucleotides stabilized by locked nucleic acids,https://doi.org/10.1093/nar/30.9.1911,PS,CATGTCATGACGGTTAGG,tpCtpAtpTtpGtpTtpCtpAtpTtpGtpAtpCtpGtpGtpTtpTtpAtpGtpG,10,frozen human serum,100,37,DNA,,1,
Design of antisense oligonucleotides stabilized by locked nucleic acids,https://doi.org/10.1093/nar/30.9.1911,LNA 20,CATGTCATGACGGTTAGG,lnaCATGTCATGACGGTTAGlnaG,4,frozen human serum,100,37,DNA,,1,
Design of antisense oligonucleotides stabilized by locked nucleic acids,https://doi.org/10.1093/nar/30.9.1911,LNA 19,CATGTCATGACGGTTAGG,lnaClnaATGTCATGACGGTTAlnaGlnaG,5,frozen human serum,100,37,DNA,,1,
Design of antisense oligonucleotides stabilized by locked nucleic acids,https://doi.org/10.1093/nar/30.9.1911,LNA 18,CATGTCATGACGGTTAGG,lnaClnaAlnaTGTCATGACGGTTlnaAlnaGlnaG,17,frozen human serum,100,37,DNA,,1,
Design of antisense oligonucleotides stabilized by locked nucleic acids,https://doi.org/10.1093/nar/30.9.1911,LNA 17,CATGTCATGACGGTTAGG,lnaClnaAlnaTlnaGTCATGACGGTlnaTlnaAlnaGlnaG,15,frozen human serum,100,37,DNA,,1,
Design of antisense oligonucleotides stabilized by locked nucleic acids,https://doi.org/10.1093/nar/30.9.1911,LNA 16,CATGTCATGACGGTTAGG,lnaClnaAlnaTlnaGlnaTCATGACGGlnaTlnaTlnaAlnaGlnaG,15,frozen human serum,100,37,DNA,,1,
Design of antisense oligonucleotides stabilized by locked nucleic acids,https://doi.org/10.1093/nar/30.9.1911,OMe 4,CATGTCATGACGGTTAGG,omeComeAomeTomeGTCATGACGGTomeTomeAomeGomeG,12,frozen human serum,100,37,DNA,,1,
"Stability, Specific Binding Activity, and Plasma Concentration in Mice of an Oligodeoxynucleotide Modified at 5'-Terminal with Poly (ethylene glycol)",https://doi.org/10.1248/bpb.18.474,ODN PO,ATGGAGAAAAAAATC,ATGGAGAAAAAAATC,1.01,human plasma,40,37,DNA,,0,
"Stability, Specific Binding Activity, and Plasma Concentration in Mice of an Oligodeoxynucleotide Modified at 5'-Terminal with Poly (ethylene glycol)",https://doi.org/10.1248/bpb.18.474,ODN SO,ATGGAGAAAAAAATC,tpAtpTtpGtpGtpAtpGtpAtpAtpAtpAtpAtpAtpAtpTtpC,5.32,human plasma,40,37,DNA,,1,
"Stability, Specific Binding Activity, and Plasma Concentration in Mice of an Oligodeoxynucleotide Modified at 5'-Terminal with Poly (ethylene glycol)",https://doi.org/10.1248/bpb.18.474,ODN PEG-PO,ATGGAGAAAAAAATC,halpegATGGAGAAAAAAATC,2.37,human plasma,40,37,DNA,,1,
"Stability, Specific Binding Activity, and Plasma Concentration in Mice of an Oligodeoxynucleotide Modified at 5'-Terminal with Poly (ethylene glycol)",https://doi.org/10.1248/bpb.18.474,ODN PO,ATGGAGAAAAAAATC,ATGGAGAAAAAAATC,0.64,mouse plasma,40,37,DNA,,0,
"Stability, Specific Binding Activity, and Plasma Concentration in Mice of an Oligodeoxynucleotide Modified at 5'-Terminal with Poly (ethylene glycol)",https://doi.org/10.1248/bpb.18.474,ODN SO,ATGGAGAAAAAAATC,tpAtpTtpGtpGtpAtpGtpAtpAtpAtpAtpAtpAtpAtpTtpC,3.78,mouse plasma,40,37,DNA,,1,
"Stability, Specific Binding Activity, and Plasma Concentration in Mice of an Oligodeoxynucleotide Modified at 5'-Terminal with Poly (ethylene glycol)",https://doi.org/10.1248/bpb.18.474,ODN PEG-PO,ATGGAGAAAAAAATC,halpegATGGAGAAAAAAATC,1.05,mouse plasma,40,37,DNA,,1,